Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

66,003 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Lee W, Kim DK, Synn CB, Lee HK, Park S, Jung DS, Choi Y, Kim JH, Byeon Y, Kim YS, Lee S, Lee S, Joo Y, Lee EJ, Yun MR, Heo SG, Yang W, Jung JE, Kim EK, Park J, Park JD, Lee DJ, Kim HW, Lim SM, Hong MH, Ahn BC, Lee JB, Pyo KH. Lee W, et al. Among authors: park s, park jd, park j. Front Oncol. 2022 Mar 9;12:821391. doi: 10.3389/fonc.2022.821391. eCollection 2022. Front Oncol. 2022. PMID: 35356198 Free PMC article.
SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.
Synn CB, Kim SE, Lee HK, Kim MH, Kim JH, Lee JM, Jo HN, Lee W, Kim DK, Byeon Y, Kim YS, Yun MR, Park CW, Yun J, Lim S, Heo SG, Yang SD, Lee EJ, Lee S, Choi H, Lee YW, Cho JS, Kim DH, Park S, Kim JH, Choi Y, Lee SS, Ahn BC, Kim CG, Lim SM, Hong MH, Kim HR, Pyo KH, Cho BC. Synn CB, et al. Among authors: park s, park cw. Clin Transl Immunology. 2021 Dec 29;11(1):e1364. doi: 10.1002/cti2.1364. eCollection 2022. Clin Transl Immunology. 2021. PMID: 35003748 Free PMC article.
66,003 results
You have reached the last available page of results. Please see the User Guide for more information.